Clay Siegall is a Leader in the Modern Pharmaceutical Sector

Clay Siegall is a pharmaceutical executive with over two decades of experience. He is the brains behind Seattle Genetics, a pharmaceutical company that develops cancer drugs. Besides being a co-founder of Seattle Genetics, he also serves as the chief executive officer and chairperson of the company’s board. Siegall’s scientific expertise focuses on the development of cancer therapies. Using his knowledge of drug development, he created Seattle Genetics to focus on scientific innovations that help cancer patients.

Seattle Genetics

ADCETRIS is the flagship product of Seattle Genetics. This drug was developed using the antibody-drug conjugates (ADC) technology. Under Siegall’s leadership, Seattle Genetics successfully developed the drug and released it to the public. The FDA also approved ADCETRIS as the first drug to be developed using the ADC technology. Siegall met with the leadership team of Takeda Pharmaceutical Company. During the meeting, Takeda agreed to collaborate with Seattle Genetics in the distribution of ADCETRIS to over 60 nations.

Besides the FDA approval, Seattle Genetics also obtained several licenses for its antibody-drug conjugates technology. The licenses allowed companies such as Pfizer, Genentech, GlaxoSmithKline and AbbVie to use the ADC technology. Seattle Genetics amassed $325 million in revenue from the innovation. Furthermore, the company is currently testing multiple ADCs. In 2001, the company signed an initial public offering under Siegall’s leadership. Seattle Genetics also amassed over $1.2 billion from public and private financing.

Professional and Academic Background

Clay Siegall was instrumental in building several pharmaceutical companies. Bristol-Myers Squibb Pharmaceutical Research Institute benefited from his expertise, as he was an executive from 1991 to 1997. The National Institutes of Health also hired him for three years as a scientist. Siegall is currently a member of Washington Roundtable, Ultragenyx Pharmaceutical, and Alder Biopharmaceuticals board of directors. In 2013, the University of Maryland awarded him the Alumnus of the Year award. He received this award because of his excellence in natural sciences, math, and computer fields. In 2012, he also won the Young Entrepreneur of the Year award presented by the Pacific Northwest Ernst. As a scholar, Siegall graduated with a Ph.D. in Genetics after attending the George Washington University. Siegall also attended the University of Maryland for his bachelor’s degree in Zoology.